Yarrow Bioscience, Inc. Common Stock
YARW
37 hedge funds and large institutions have $1.84M invested in Yarrow Bioscience, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 37 → 37 (0)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
43% less capital invested
Capital invested by funds: $3.25M → $1.84M (-$1.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$30.7K |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$24.6K |
| 3 |
Jane Street
New York
|
+$17.9K |
| 4 |
Millennium Management
New York
|
+$12.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$53.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$50K |
| 3 |
Citigroup
New York
|
-$16K |
| 4 |
RC
RegentAtlantic Capital
Morristown,
New Jersey
|
-$10K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$7K |
YARW Hedge Fund Activity: Q3 2022 in Review
37 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q3 2022, worth a combined $1.84M — down 43% from $3.25M a quarter earlier.
Fund positioning in YARW was balanced in Q3 2022: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 6 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $30.7K. The largest seller was Vanguard Group, cutting an estimated $53.8K.
- 37 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $1.84M of Yarrow Bioscience, Inc. Common Stock stock for Q3 2022, down 43% quarter-over-quarter.
- 6 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q3 2022 and 6 closed out, a net change of 0 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q3 2022 was Citadel Advisors, an estimated $30.7K added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $53.8K sold.
Based on aggregated 13F filings for Q3 2022.